Monitor for future disclosures on the search for a permanent CEO and any changes in strategic direction under interim leadership. The resignation may raise questions about company stability given its small market cap of $25M.
Price Chart
Executive Summary
Cue Biopharma's CEO and board member Usman Azam resigned, and Lucinda Warren was appointed interim CEO. Dr. Azam has been withdrawn as a director nominee for the upcoming annual meeting, and the board size has been reduced to six. This is a management transition with no immediate financial impact disclosed.
Key Financial Metrics
Key Facts
- Usman Azam resigned as President, CEO, and board member effective March 26, 2026
- Lucinda Warren, Chief Financial and Business Officer, appointed Interim President and CEO effective March 27, 2026
- Dr. Azam was withdrawn as a director nominee for the 2026 Annual Meeting
- Board size reduced from seven to six directors
- No replacement nominee is being added
- Filing is a supplement to the existing proxy statement for the April 13, 2026 annual meeting
Financial Impact
No financial impact disclosed; separation agreement details not provided
Risk Factors
- Leadership uncertainty during interim period
- Potential disruption in strategy or operations
- Market perception of instability at a small-cap biotech company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-129007 |
| Document: 0001193125-26-129007-index-headers.html | 0001193125-26-129007 |
| Document: 0001193125-26-129007-index.html | 0001193125-26-129007 |
| Document: 0001193125-26-129007.txt | 0001193125-26-129007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 9w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers